Our Development Pipeline
TMB-002, a proprietary topical rapamycin, is being developed for the treatment of facial angiofibromas (FA) and tuberous sclerosis complex (TSC). Efficacy has been demonstrated in multiple well controlled studies and dozens of published case reports for topical mTOR inhibitors that have been compounded in the past. However, there is no commercial formulation available. TMB-002 is a room temperature stable 1% formulation of rapamycin with a high level of content uniformity. Timber recently completed a Phase 2b study for TMB-002 and anticipates reporting top line data in Q3 2022.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.